Celltrion’s Global Ambitions On Track As Third Biosimilar Approved In US
Executive Summary
With the US approval of its third biosimilar product, Herzuma, Korean group Celltrion appears to be on a continued growth track in the global market, despite intensifying competition. The company is counting on Herzuma’s potential to rapidly replace Herceptin in the world’s biggest pharma market, given the higher price of the original drug.